Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Esme Needham | January 15, 2026 | News story | Sales and Marketing | Arkin Capital, biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed to invest in pre-clinical and early clinical-stage biotechnology companies whose work has the potential to address high unmet medical need.
Arkin Bio Ventures III builds on two previous funds, Arkin Bio Ventures I in 2016 and Arkin Bio Ventures II in 2020. The latest fund is intended to combine scientific knowledge with expertise in drug development, addressing therapeutic areas that lack effective treatment options. The fund was created in close collaboration with founders of biotechnology companies, addressing areas such as biological strategy and clinical positioning in order to create value-driven companies that would be attractive for both investment and partnership.
The fund’s strategy is designed around extensive knowledge of the needs of investors and pharmaceutical partners and is led by Dr Pini Orbach. The fund will invest in between ten and 12 companies around the world. It is particularly interested in areas such as oncology, immunology, inflammation and rare diseases.
Investors in the fund included Phoenix Insurance, Clal Insurance and Amitim Pension Funds. Arkin Capital also made an investment.
Following the closing of the latest fund, Arkin Bio manages biotechnology assets totalling over $600m in value.
“We launched Arkin Bio Ventures III to deepen our commitment to frontline science and the teams bringing it to life,” said Dr Pini Orbach, managing partner at Arkin Bio. “This fund allows us to lean further into advanced pre-clinical opportunities and help accelerate private companies in order to bring breakthrough technologies to proof-of-concept.”
Founded in 2009, Arkin Capital is an investment management company.
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
